Search papers, labs, and topics across Lattice.
This paper introduces a two-stage pipeline, CausalFlow-T, for estimating treatment effects from incomplete longitudinal EHR data by combining a DAG-constrained normalizing flow for counterfactual inference with an LLM-driven evolutionary imputer to handle MNAR missingness. CausalFlow-T uses LSTM-encoded patient history to perform exact invertible counterfactual inference, addressing time-varying confounding, while the LLM-driven imputer proposes executable imputation operators to improve imputation accuracy and preserve ATE recovery. Experiments on synthetic, semi-synthetic, and real-world EHR data demonstrate the pipeline's superior performance in handling high levels of MNAR missingness and accurately estimating treatment effects, specifically showing a weight-loss difference favoring GLP-1 receptor agonists in type 2 diabetes patients, consistent with RCT evidence.
LLMs can now impute missing healthcare data well enough to improve causal treatment effect estimation from real-world EHRs, even with 80% missingness.
Target trial emulation (TTE) enables causal questions to be studied with observational data when randomized controlled trials (RCTs) are infeasible. Yet treatment-effect methods often address causal estimation, missingness, and temporal structure separately, limiting their robustness in electronic health records (EHRs), where time-varying confounding and missing-not-at-random (MNAR) biomarkers can reach 50%--80%. We propose a two-stage pipeline for treatment effect estimation from incomplete longitudinal EHRs. First, CausalFlow-T, a directed acyclic graph (DAG)-constrained normalizing flow with long short-term memory (LSTM)-encoded patient history, performs exact invertible counterfactual inference, avoiding approximation errors from variational inference and separating confounding through explicit causal structure. Ablations on four synthetic and one semi-synthetic benchmark with known counterfactuals show that DAG constraints and exact inference address distinct failure modes: neither compensates for the other. Second, because CausalFlow-T requires completed inputs, we introduce an LLM-driven evolutionary imputer that proposes executable imputation operators rather than individual entries, and evaluate it with three large language model (LLM) backends, including two open-source models. Across 30%--80% MNAR missingness, this imputer achieves the best pooled rank over biomarker and causal metrics, leading in point-wise accuracy and temporal extrapolation while preserving average treatment effect (ATE) recovery as statistical baselines degrade. On Swiss primary-care EHRs from adults with type 2 diabetes initiating a GLP-1 receptor agonist or SGLT-2 inhibitor, the pipeline estimates a per-protocol weight-loss difference of -0.98 kg [95% CI -1.01, -0.96] favoring GLP-1 receptor agonists, consistent with randomized evidence and obtained from realistically incomplete real-world EHRs.
